Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial
Authors
Meng‐Yao Lu (ORCID: https://orcid.org/0000-0003-4461-9967)
Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial
Meng‐Yao Lu, Karen Sinclair, Alphan Küpesiz, Yogi Chopra et al.
Journal
Haematologica
Topics
Hematopoietic Stem Cell Transplantation
article
Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial
Meng‐Yao Lu, Karen Sinclair, Alphan Küpesiz, Yogi Chopra, T Güngör, Federica Locatelli, Ho Joon Im, Maria Gabriela Matos, Séverine Peyrard, Tommaso Stefanelli, Yvonne S. Smith, Cristina Díaz-de-Heredia, Bulent Antmen, Sunil Bhat, Hyoung Jin Kang, Yoshiyuki Takahashi, Katsuyoshi Koh
article en
Abstract
No abstract available for this paper.
Publication Tag
Haematologica
Institutions
Novartis (Switzerland) (CH), Akdeniz University (TR), Hospital for Sick Children (CA), Asan Medical Center (KR), Narayana Health (IN), University of Ulsan (KR), Novartis (France) (FR), Support group for adolescents and children with cancer (BR), Saitama Children's Medical Center (JP), Vall d'Hebron Institut de Recerca (ES), Seoul National University Children's Hospital (KR), Akdeniz University Hospital (TR), Bambino Gesù Children's Hospital (IT), Vall d'Hebron Hospital Universitari (ES), University Children's Hospital Zurich (CH), National Taiwan University Hospital (TW), Novartis (Ireland) (IE), Adana Science and Technology University (TR), Nagoya University (JP)
Funders
Novartis Pharmaceuticals Corporation, Novartis Pharma, Novartis Pharmaceuticals UK Limited
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial — Meng‐Yao Lu, Karen Sinclair, et al. · Haematologica (2026) | TGRS Research Map | TGRS